Theralase Technologies Inc.
TSX VENTURE : TLT

Theralase Technologies Inc.

November 17, 2010 09:02 ET

Theralase Launches Laser Sales Team Dedicated to the Horse Industry

TORONTO, ONTARIO--(Marketwire - Nov. 17, 2010) - Theralase Technologies Inc. (TSX VENTURE:TLT) has launched a laser sales team dedicated to the sales of the Company's products to the horse industry.

The Theralase sales team will supply therapeutic medical laser technology to veterinarians, horse owners and trainers that is able to reduce pain and inflammation, while stimulating the growth of new tissue, substantially speeding the return of their equine athletes to top performance.

To accomplish this, Theralase has added an experienced sales team to service the horse industry, including Doug Nash and David Groves. Mr. Nash has over 30 years of hands-on experience in the standardbred industry and is an instructor teaching courses through Equine Guelph and the REACH campus at the University of Guelph. Mr. Groves, President, Equine World Sales Division has been with Theralase for 5 years and has over 20 years experience in the North American healthcare market successfully launching healthcare products. 

Doug Nash stated, "My involvement with Theralase stems from the positive results I have witnessed firsthand with the technology in the alleviation of pain and inflammation and the promotion of healing. I am delighted results of the Theralase technology have proven to be both safe and highly effective for treating a wide range of neural muscular skeletal treatments in horses, including acupuncture, using predetermined protocols."

David Groves stated, "We have consistently demonstrated superior patient outcomes in the human market by accelerating the healing process; therefore, it was a natural extension of proven clinical outcomes applied to the equine athlete. Based on the equine results to date, we can confidently offer a pain-free and non-invasive modality to treat common pain and inflammatory conditions in the thoroughbred, standardbred and championship equine markets."

Dr. Terry Ruch a member of the Theralase Medical and Scientific Advisory Board stated, "I am glad to see Theralase expand their presence in the equine market. The Theralase is able to increase efficacy, provide superior clinical outcomes and allow for faster return to competition for many equine athletes. The Theralase works extremely well at reducing pain and inflammation, working on numerous soft tissue injuries, such as: muscles, tendons and ligaments."

Roger Dumoulin-White, President and CEO of Theralase Inc. stated, "The Company is delighted to have two seasoned professionals, Doug and David, to head up our equine sales team, utilizing the vast knowledge of equine soft tissue injuries that Dr. Ruch possesses. All members bring decades of hands-on experience to the table, which will ultimately benefit the Company in both expanded knowledge of the horse industry and increased revenue."

Visit the corporate or regulatory website at www.theralase.com or www.sedar.com for more information.

About Theralase Technologies Inc.

Theralase Technologies Inc. designs, develops and manufactures patented, super-pulsed laser technology utilized in bio-stimulation and bio-destruction applications. The technology is safe and effective in the treatment of chronic pain, neural muscular-skeletal conditions and wound care. When combined with patented light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target and destroy cancers, bacteria and viruses. 

This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

  • Theralase Technologies Inc.
    Roger Dumoulin-White
    President and CEO
    1.866.843.5273
    rwhite@theralase.com